HALO Healthcare

Halozyme Therapeutics, Inc.

$128.62-0.26%

Price as of close on Nov 3, 2026 · Financials updated Oct 9, 2026

Basics

Sector: Healthcare
Industry: Biotechnology
Country: United States
Market cap: 14.6B USD
Enterprise value: 15.8B USD
Full-time employees: 423

Overall health

Strength: more profitable than most peersmore profitable than peers
Strength: growing faster than most peersgrowing faster than peers
Drawback: higher risk than most peers: more debt relative to equity (14.95× vs a peer median of 0.22×)higher risk: more debt vs equity (14.95× vs peers 0.22×)
About average: valuation

Ranks #401 of 1,157 healthcare companies (top 35%)

See how it ranks against its peers

Worth knowing

Much more borrowing than peers. Debt is 15.0× equity vs a peer median of 0.2×.Debt is 15.0× equity vs peers 0.2×.
Debt is 15.0× shareholders' equity, against a peer median of 0.2×, among the highest 10% of its peer group.Debt is 15.0× shareholders' equity, vs peers 0.2×, among the highest 10% of its peer group.
Operating margin at a 6-year low. 34% in 2025, the weakest of the last 6 years.
Halozyme Therapeutics's operating margin fell to 34% in 2025, its lowest in the 6 years of filings we have.
Sales growing faster than profits. Since 2022: revenue +112%, operating profit +75%.
Since 2022, Halozyme Therapeutics's revenue changed +112% but operating profit only +75%: costs are rising faster than sales.
Share count shrinking. Shares outstanding down 16% from December 2022 to July 2026.
Halozyme Therapeutics had 16% fewer shares at July 2026 than at December 2022, mainly through buybacks, so each remaining share owns a larger slice of the business.

StockQuotient Score

59/ 100

Oct 5 60 → Nov 4 59 (-1)

Valuation

Is the price right?

53/100

Moderate

3/3 inputs reported · High confidence

Since last quarter: ▲ Stronger

Share count down 4.3%

Valuation also moves with the share price every day.

Why

Close to the peer norm on every measure.

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield2.8%

SEC filings · 12 months to Jun 2026Reported value30% base weight · Z-score 0.92Sector median: 0.0148 · MAD: 0.0148

EBITDA yield3.7%

SEC filings · 12 months to Jun 2026Reported value50% base weight · Z-score -0.08Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield5.5%

SEC filings · 12 months to Jun 2026 · operating cash flow − capital spendingReported value20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield1.0%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

80/100

Strong▼ 1 since Oct 27 close

3/3 inputs reported · High confidence

Since last quarter: ▲ Stronger

12-month revenue up 10.3%

Why it changed since the Oct 27, 2026 close: Score 81 → 80

Peer companies moved-1

Each step re-scores the company against its peers as they were on Oct 28, 2026; the parts add up to the change. Price effects on EBITDA yield are approximate.

Why

Stronger than most peers on:

▲ Revenue growth
▲ 3-yr revenue

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growth-23.5%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -1.11Sector median: 0.0976 · MAD: 0.2991

3-year revenue growth29.1%

SEC filings · 3 years to Jun 2026Reported value33% base weight · Z-score 2.76Sector median: 0.0584 · MAD: 0.0840

Revenue growth41.2%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score 3.60Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

95/100

Strong

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Stronger than most peers on:

▲ Operating margin
▲ ROA
▲ ROIC

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin35.9%

SEC filings · 12 months to Jun 2026Outlier capped at sector 5th/95th percentile33% base weight · Z-score 2.16Sector median: 0.0706 · MAD: 0.1217

Return on assets16.0%

SEC filings · 12 months to Jun 2026Outlier capped at sector 5th/95th percentile33% base weight · Z-score 2.47Sector median: 0.0166 · MAD: 0.0537

Return on invested capital22.2%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score 1.74Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin82.4%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity288.1%

SEC filings · 12 months to Jun 2026Outlier capped at sector 5th/95th percentileInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Higher

Higher relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Weaker than most peers on:

▼ Debt / equity
▼ Beta

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta0.88

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score -0.75Sector median: 0.6250 · MAD: 0.3380

Current ratio2.71×

SEC filings · latest balance sheetReported value33% base weight · Z-score 0.09Sector median: 2.5860 · MAD: 1.3850

Debt / equity14.95×

SEC filings · latest balance sheetOutlier capped at sector 5th/95th percentile33% base weight · Z-score -9.77Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Halozyme Therapeutics

Is Halozyme Therapeutics getting weaker?: Its latest SEC filing (Aug 6, 2026) got stronger: share count down 4.3%. Its overall score is unchanged at 59/100 since Oct 28, 2026.
How is Halozyme Therapeutics valued vs its peers?: Priced about in line with its peers. Valuation scores 53/100 against 1,393 healthcare peers.
Is Halozyme Therapeutics growing?: Yes, faster than most of its peers. Growth scores 80/100 against 1,393 healthcare peers. Revenue growth 41.2% vs a peer median of 6.1% (stronger than 89% of peers).Revenue growth 41.2% vs peers 6.1% (stronger than 89% of peers). Earnings per share growth -23.5% vs a peer median of 9.8% (weaker than 71% of peers).Earnings per share growth -23.5% vs peers 9.8% (weaker than 71% of peers).
How profitable is Halozyme Therapeutics?: More profitable than most of its peers. Profitability scores 95/100 against 1,393 healthcare peers. Operating margin 35.9% vs a peer median of 7.1% (stronger than 95% of peers).Operating margin 35.9% vs peers 7.1% (stronger than 95% of peers).
How risky is Halozyme Therapeutics?: Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Debt / equity 14.95× vs a peer median of 0.22× (weaker than 100% of peers).Debt / equity 14.95× vs peers 0.22× (weaker than 100% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Aug 6, 2026 · compared with the quarter ended Mar 31, 2026

Got stronger

Share count down 4.3%

	Previous quarter	Latest quarter	Change
Revenue (12 months)	1.5B USD	1.7B USD	+10.3%
Net income (12 months)	348.8M USD	413.6M USD	+18.6%
Operating margin	33.9%	35.9%	+2.0 pts
Free cash flow (12 months)	667.7M USD	806.2M USD	+20.8%
Debt	2.1B USD	2.1B USD	+0.1%
Cash	309.7M USD	163.1M USD	−47.3%
Shares outstanding	118.6M	113.5M	−4.3%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Biotechnology · 132 companies

Valuations in Biotechnology are within their usual range since 2016.

48% of months since 2016 were valued lower than now.
22% of companies are in the most expensive fifth of their own price-to-sales history.
Median price-to-sales is +530% vs the whole market, against a usual +637%.

2016Shaded: most expensive fifth of its range2026

Earnings-based measures are left out for now because many companies in Biotechnology are losing money.

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Gross margin	81.6%	78.9%	76.8%	84.3%	83.6%	▼ 0.7 pts
Operating margin	62.2%	40.5%	40.7%	54.3%	33.6%	▼ 21 pts
Net margin	90.8%	30.6%	34.0%	43.7%	22.7%	▼ 21 pts
Return on assets (ROA)	36.5%	11.0%	16.2%	21.5%	12.5%	▼ 9.0 pts
Return on equity (ROE)	204.5%	119.0%	336.0%	122.1%	—	—
Free cash flow margin	67.2%	35.6%	45.0%	46.1%	46.2%	▲ 0.0 pts
Current ratio	7.91×	5.65×	6.64×	7.80×	4.66×	▼ 40%
Quick ratio	7.45×	4.88×	5.50×	6.78×	3.66×	▼ 46%
Debt to equity	4.45×	8.87×	17.89×	4.14×	—	—
Interest coverage	36.66×	15.79×	17.99×	30.48×	25.87×	▼ 15%

HALO price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Strength: more profitable than most peersmore profitable than peers

Strength: growing faster than most peersgrowing faster than peers

Drawback: higher risk than most peers: more debt relative to equity (14.95× vs a peer median of 0.22×)higher risk: more debt vs equity (14.95× vs peers 0.22×)

About average: valuation

Ranks #401 of 1,157 healthcare companies (top 35%)

See how it ranks against its peers

Worth knowing

Much more borrowing than peers. Debt is 15.0× equity vs a peer median of 0.2×.Debt is 15.0× equity vs peers 0.2×.

Debt is 15.0× shareholders' equity, against a peer median of 0.2×, among the highest 10% of its peer group.Debt is 15.0× shareholders' equity, vs peers 0.2×, among the highest 10% of its peer group.

Operating margin at a 6-year low. 34% in 2025, the weakest of the last 6 years.

Halozyme Therapeutics's operating margin fell to 34% in 2025, its lowest in the 6 years of filings we have.

Sales growing faster than profits. Since 2022: revenue +112%, operating profit +75%.

Since 2022, Halozyme Therapeutics's revenue changed +112% but operating profit only +75%: costs are rising faster than sales.

Share count shrinking. Shares outstanding down 16% from December 2022 to July 2026.

Halozyme Therapeutics had 16% fewer shares at July 2026 than at December 2022, mainly through buybacks, so each remaining share owns a larger slice of the business.

Questions investors ask about Halozyme Therapeutics

Is Halozyme Therapeutics getting weaker?

Its latest SEC filing (Aug 6, 2026) got stronger: share count down 4.3%. Its overall score is unchanged at 59/100 since Oct 28, 2026.

How is Halozyme Therapeutics valued vs its peers?

Priced about in line with its peers. Valuation scores 53/100 against 1,393 healthcare peers.

Is Halozyme Therapeutics growing?

Yes, faster than most of its peers. Growth scores 80/100 against 1,393 healthcare peers. Revenue growth 41.2% vs a peer median of 6.1% (stronger than 89% of peers).Revenue growth 41.2% vs peers 6.1% (stronger than 89% of peers). Earnings per share growth -23.5% vs a peer median of 9.8% (weaker than 71% of peers).Earnings per share growth -23.5% vs peers 9.8% (weaker than 71% of peers).

How profitable is Halozyme Therapeutics?

More profitable than most of its peers. Profitability scores 95/100 against 1,393 healthcare peers. Operating margin 35.9% vs a peer median of 7.1% (stronger than 95% of peers).Operating margin 35.9% vs peers 7.1% (stronger than 95% of peers).

How risky is Halozyme Therapeutics?

Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Debt / equity 14.95× vs a peer median of 0.22× (weaker than 100% of peers).Debt / equity 14.95× vs peers 0.22× (weaker than 100% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

1.5B USD

1.7B USD

+10.3%

Net income (12 months)

348.8M USD

413.6M USD

+18.6%

Operating margin

33.9%

35.9%

+2.0 pts

Free cash flow (12 months)

667.7M USD

806.2M USD

+20.8%

Debt

2.1B USD

2.1B USD

+0.1%

Cash

309.7M USD

163.1M USD

−47.3%

Shares outstanding

118.6M

113.5M

−4.3%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Gross margin

81.6%

78.9%

76.8%

84.3%

83.6%

▼ 0.7 pts

Operating margin

62.2%

40.5%

40.7%

54.3%

33.6%

▼ 21 pts

Net margin

90.8%

30.6%

34.0%

43.7%

22.7%

▼ 21 pts

Return on assets (ROA)

36.5%

11.0%

16.2%

21.5%

12.5%

▼ 9.0 pts

Return on equity (ROE)

204.5%

119.0%

336.0%

122.1%

—

Free cash flow margin

67.2%

35.6%

45.0%

46.1%

46.2%

▲ 0.0 pts

Current ratio

7.91×

5.65×

6.64×

7.80×

4.66×

▼ 40%

Quick ratio

7.45×

4.88×

5.50×

6.78×

3.66×

▼ 46%

Debt to equity

4.45×

8.87×

17.89×

4.14×

—

Interest coverage

36.66×

15.79×

17.99×

30.48×

25.87×

▼ 15%